Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00920205 · ClinicalTrials.gov registry record · Phase 1
Safety Study of MPC-3100 in Cancer Patients Who Have Failed Other Treatments
A Phase 1 study of Cancer, sponsored by Myrexis.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 3
- Study locations
NCT00920205 is a Phase 1 study of Cancer that has completed, run by Myrexis. The registered enrollment target is 26 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT00920205, a Phase 1 study of Cancer, has completed, sponsored by Myrexis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to see how safe the study drug is and to determine the best dose to use in cancer patients in the future. The study drug is designed to reduce the activity of a protein known as "heat shock protein 90", or "Hsp90". Hsp90 is found in every cell in the human body and normally helps those cells (and the body) cope with stressful situations. In certain cancers, however, Hsp90 helps the cancer cells survive and grow. By reducing the activity of Hsp90, the study drug may slow the growth, and reduce the survival, of those cancer cells.
Conditions Studied
Interventions
- DRUG MPC-3100 (an Hsp90 inhibitor)
Study Locations (3)
Nevada
- Nevada Cancer Institute - Las Vegas
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Texas
- South Texas Accelerated Research Therapeutics - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2009-06 |
| Est. Completion | 2011-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00920205
The ClinicalTrials.gov registry entry for NCT00920205 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Myrexis, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which MPC-3100 (an Hsp90 inhibitor) is the first listed.
NCT00920205 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Nevada, Pennsylvania, Texas.
Frequently Asked Questions
What is clinical trial NCT00920205 about?
NCT00920205 is a clinical study titled "Safety Study of MPC-3100 in Cancer Patients Who Have Failed Other Treatments". The purpose of this study is to see how safe the study drug is and to determine the best dose to use in cancer patients in the future. The study drug is designed to reduce the activity of a protein known as "heat shock protein 90", or "Hsp90". Hsp90 is found in every cell in the human body and norm...
What is the current status of trial NCT00920205?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2009-06. Estimated completion is 2011-06.
What conditions does trial NCT00920205 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT00920205?
The interventions under investigation include: MPC-3100 (an Hsp90 inhibitor) (DRUG).
Who is sponsoring clinical trial NCT00920205?
This trial is sponsored by Myrexis, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00920205 being conducted?
This trial has 3 study locations across Nevada, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.